Vaccine for deadliest form of skin cancer nearly halves risk

Pharmaceutical companies Moderna and Merck have announced the results of a phase 3 clinical trial for a new mRNA-based vaccine designed to combat melanoma. The treatment, known as intismeran autogene, is personalized to match the specific genetic profile of an individual patient's tumor. Data indicates that the vaccine reduces the risk of melanoma recurrence or death by 42 percent when used alongside standard treatments. Furthermore, the therapy reportedly lowers the risk of the cancer spreading to other parts of the body or resulting in patient mortality by 38 percent.

While these results offer a promising development in oncology, the vaccine still requires formal approval from health authorities in the United States before it can be widely distributed. Participants in the clinical study experienced side effects consistent with earlier trials, including common symptoms such as fatigue, chills, and localized pain at the injection site. Further regulatory review is necessary to determine the next steps for bringing this personalized immunotherapy to patients worldwide.